Ballentine Partners LLC Makes New $227,000 Investment in Moderna, Inc. $MRNA

Ballentine Partners LLC bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 8,226 shares of the company’s stock, valued at approximately $227,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. S Bank Fund Management Ltd bought a new position in Moderna during the first quarter worth about $25,000. SVB Wealth LLC bought a new position in Moderna during the first quarter worth about $28,000. CX Institutional boosted its holdings in Moderna by 1,129.8% during the second quarter. CX Institutional now owns 1,033 shares of the company’s stock worth $29,000 after buying an additional 949 shares during the last quarter. Costello Asset Management INC bought a new position in Moderna during the first quarter worth about $30,000. Finally, Sentry Investment Management LLC bought a new position in Moderna during the first quarter worth about $31,000. Institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on MRNA shares. JPMorgan Chase & Co. set a $26.00 target price on Moderna in a report on Friday, August 1st. Morgan Stanley reiterated an “equal weight” rating and set a $32.00 price objective on shares of Moderna in a report on Friday, August 1st. Wells Fargo & Company reiterated an “equal weight” rating on shares of Moderna in a report on Sunday, July 13th. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, June 2nd. Finally, Barclays cut their price objective on Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a report on Monday, August 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, fourteen have given a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $41.81.

Moderna Stock Performance

NASDAQ MRNA opened at $25.33 on Tuesday. The stock has a market capitalization of $9.86 billion, a price-to-earnings ratio of -3.36 and a beta of 1.93. The stock’s 50 day moving average price is $26.80 and its two-hundred day moving average price is $27.50. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $67.96.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The business’s quarterly revenue was down 41.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.